Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine LAI and UZEDY® commercial progress
July 31, 2024
July 31, 2024
Medincell to Present Data Showing Enhanced Potential of Tumor-Targeting Monoclonal Antibody in Melanoma Using BEPO® Technology at he CRS Annual Meeting
July 1, 2024
July 1, 2024
H.C. Wainwright & Co. Initiates MedinCell’s Coverage with a “Buy” Recommendation
Medincell publishes its consolidated annual financial results
June 10, 2024
June 10, 2024
Publication of the financial results for the 2023-2024 fiscal year and videoconference on Monday, June 10, 2024
June 3, 2024
June 3, 2024
Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate)
June 3, 2024
June 3, 2024
Update of the 2024 financial calendar
May 27, 2024
May 27, 2024
[Replay] Videoconference: Company’s Latest News, Outlook, and R&D Activities
